TheraRadar
← Back
Data updated: Jun 28, 2026

INTL MEDICATION SYS

Generics
CardiovascularMetabolic

INTL MEDICATION SYS is a generic drug manufacturer focused on Cardiovascular, Metabolic.

1982
Since
10
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules

INTL MEDICATION SYS's Key Drugs

INTL MEDICATION SYS's core commercial portfolio centers on CALCIUM CHLORIDE 10%, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.

CALCIUM CHLORIDE 10%
Other
Approved 2017

INTL MEDICATION SYS's Recent FDA Approvals

INTL MEDICATION SYS secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

INTL MEDICATION SYS's Therapeutic Areas

INTL MEDICATION SYS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
1 drugs
Metabolic 50%
1 drugs

INTL MEDICATION SYS's Top Competitors

INTL MEDICATION SYS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Metabolic, Cardiovascular
Baxter specialty
Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Cardiovascular
B BRAUN specialty
Metabolic, Cardiovascular
AstraZeneca big-pharma
Metabolic, Cardiovascular

INTL MEDICATION SYS Pipeline Snapshot

Active clinical trials for INTL MEDICATION SYS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CALCIUM CHLORIDE 10% leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling